Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of ruxolitinib cream in prurigo nodularis
NL-OMON59279Phase 3Completed
- Sponsor
- Incyte
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prurigo nodularis (PN) comparing Ruxolitinib cream with Vehicle control (2 arms). Primary endpoint: WI-NRS4 response at Week 12. Started Oct 2023; status: completed.
02
Drugs
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NL-OMON59279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59279.